Overview

Novel Experimental COVID-19 Therapies Affecting Host Response

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Treatments:
Angiotensin I (1-7)